Drug & intervention

cyclosporine

RxCUI 3008

Clinical trials16
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Ciclosporin

Ciclosporin, also spelled cyclosporine and cyclosporin, is a calcineurin inhibitor, used as an immunosuppressant medication. It is taken orally or intravenously for rheumatoid arthritis, psoriasis, Crohn's disease, nephrotic syndrome, eczema, and in organ transplants to prevent rejection. It is also used as eye drops for keratoconjunctivitis sicca (dry eyes). It is a cyclic peptide with chain length 11. Common side effects include high blood pressure, headache, kidney problems, increased hair growth, and vomiting. Other severe side effects include an increased risk of infection, liver problems, and an increased risk of lymphoma. Blood levels of the medication should be checked to decrease the risk of side effects. Use during pregnancy may result in preterm birth; however, ciclosporin does not appear to cause birth defects. Ciclosporin is believed to work by decreasing the function of lymphocytes. It does this by forming a complex with cyclophilin to block the phosphatase activity of calcineurin, which in turn decreases the production of inflammatory cytokines by T-lymphocytes. Ciclosporin was isolated in 1971 from the fungus Tolypocladium inflatum and came into medical use in 1983. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 179th most commonly prescribed medication in the United States, with more than 2 million prescriptions. It is available as a generic medication.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

16 shown
A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsNCT07862114 · 2026-10-16
NOT_YET_RECRUITING
A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy AdultsNCT03768609 · 2018-12-06
COMPLETED
Drug Interaction Study of Apixaban With Cyclosporine and TacrolimusNCT03083782 · 2017-04-18
COMPLETED
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisNCT02144857 · 2014-05-30
UNKNOWN
Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy ProcedureNCT02114073 · 2014-04-01
COMPLETED
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerNCT01105650 · 2010-07-01
COMPLETED
Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney TransplantNCT00790439 · 2008-07-01
WITHDRAWN
Diabetogenicity of Cyclosporine and TacrolimusNCT00766909 · 2008-03-01
COMPLETED
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast CancerNCT00074269 · 2003-07-01
TERMINATED
Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet TransplantationNCT00286624 · 2003-03-01
COMPLETED
Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast CancerNCT00009763 · 2001-03-01
UNKNOWN
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyNCT00009750 · 2001-03-01
UNKNOWN
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerNCT00365287 · 2000-06-01
COMPLETED
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast CancerNCT00020176 · 2000-06-01
COMPLETED
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast CancerNCT00008203 · 1996-05-01
COMPLETED
Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast CancerNCT00003920 · 1996-04-01
UNKNOWN

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.